Company logo

BAYN - Bayer Aktiengesellschaft

XETRA -> Healthcare -> Drug Manufacturers—General
Leverkusen, Germany
Type: Equity

BAYN price evolution
BAYN
(in millions $) 30 Jul 2024 1 May 2024 31 Jan 2024 30 Oct 2023
Current assets
Cash
Short term investments
Net receivables $17031 $17794 $12815 $14254
Inventory $13088 $13437 $13947 $13956
Total current assets $40144 $40167 $37556 $37528
Long term investments
Property, plant & equipment $13487 $13472 $13321 $13449
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $119859 $119881 $116259 $117242
Current liabilities
Accounts payable $6127 $6398 $7456 $6500
Deferred revenue
Short long term debt
Total current liabilities $31561 $30630 $29457 $33081
Long term debt $37397 $37987 $38176 $35111
Total noncurrent liabilities
Total debt
Total liabilities $84172 $84276 $83332 $83862
Shareholders' equity
Retained earnings $14911 $14829 $12151 $12604
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 30 Dec 2021 30 Dec 2020
Current assets
Cash $4564 $4191
Short term investments $669 $1311
Net receivables $12522 $13450 $12980 $12143
Inventory $13947 $13636 $11314 $10961
Total current assets $37556 $37760 $32578 $35660
Long term investments $2612 $1998
Property, plant & equipment $13321 $13674 $12688 $11710
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $116259 $124877 $120241 $117046
Current liabilities
Accounts payable $7456 $7545 $6792 $5683
Deferred revenue
Short long term debt $4155 $8358
Total current liabilities $29457 $35084 $29403 $36728
Long term debt $38170 $33781 $35552 $32271
Total noncurrent liabilities $33193
Total debt
Total liabilities $83332 $86104 $87073 $86347
Shareholders' equity
Retained earnings $12175 $17233 $13345 $13057
Other shareholder equity -$105 $652 $17160 $14952
Total shareholder equity $33020 $30524
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Revenue
Total revenue $13765 $11862
Cost of revenue
Gross Profit $8302 $7376
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $5210 $5187
Operating income
Income from continuing operations
EBIT
Income tax expense $589 $302
Interest expense -$501 -$545
Net income
Net income $2000 $1337
Income (for common shares)
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 30 Dec 2020
Revenue
Total revenue $47637 $50739 $41400
Cost of revenue $15727
Gross Profit $27888 $30868 $25673
Operating activities
Research & development $4884
Selling, general & administrative $13886
Total operating expenses $19465 $22889 $34525
Operating income $6875
Income from continuing operations
EBIT $6875
Income tax expense $1321 $504 -$1689
Interest expense -$852 -$2708 -$1500
Net income
Net income -$2941 $4150 -$10495
Income (for common shares) -$10495
(in millions $) 30 Jul 2024 1 May 2024 31 Jan 2024 30 Oct 2023
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$2300 $303 -$3517 $367
Financing activities
Dividends paid -$113 -$2379 -$2364
Sale and purchase of stock
Net borrowings
Total cash flows from financing -$15 $677 -$679 $1774
Effect of exchange rate $36 -$12 -$185 -$6
Change in cash and equivalents -$2019 -$1182 $736 $1644
(in millions $) 31 Jan 2024 31 Jan 2023 30 Dec 2021 30 Dec 2020
Net income $1000 -$10495
Operating activities
Depreciation $1609 $3444
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $5089 $4903
Investing activities
Capital expenditures -$2611 -$2418
Investments $4302 -$4027
Total cash flows from investing -$3517 -$2381 $855 -$4073
Financing activities
Dividends paid -$2379 -$1985 -$1993 -$2751
Sale and purchase of stock
Net borrowings -$2452 $4467
Total cash flows from financing -$679 -$4220 -$5645 $423
Effect of exchange rate -$185 $112 $35 -$240
Change in cash and equivalents $736 $607 $373 $1006
Fundamentals
Market cap $19.17B
Enterprise value N/A
Shares outstanding 982.42M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 1.27
Quick ratio 0.86